Company news

Spyre Therapeutics, Inc. news in 2023

Spyre Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Aeglea BioTherapeutics Announces Name Change to Spyre Therapeutics, Appoints CEO and Additional Directors, and Expands Leadership Team to Develop Next-Generation Therapeutic Combinations for the Treatment of IBD

November 26, 2023

Aeglea BioTherapeutics Announces Grants of Inducement Awards

November 21, 2023

Aeglea BioTherapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

November 8, 2023

Aeglea BioTherapeutics to Participate in Upcoming November Investor Conferences

October 29, 2023

Aeglea BioTherapeutics to Participate in Upcoming September Conference

September 13, 2023

Aeglea BioTherapeutics Announces Reverse Stock Split

September 6, 2023

Aeglea BioTherapeutics Expands Executive Leadership Team with Appointment of Industry Veterans Scott Burrows and Heidy Abreu King-Jones

September 4, 2023

Aeglea BioTherapeutics Reports Second Quarter 2023 Financial Results

August 10, 2023

Aeglea BioTherapeutics Announces Sale of Pegzilarginase to Immedica Pharma

July 26, 2023

Aeglea BioTherapeutics Announces Grant of Inducement Awards

June 22, 2023

Aeglea BioTherapeutics Reports First Quarter 2023 Financial Results

May 10, 2023

Aeglea BioTherapeutics Announces Interim Results from Ongoing Phase 1/2 Clinical Trial of Pegtarviliase for the Treatment of Classical Homocystinuria and Begins Process to Explore Strategic Alternatives

April 11, 2023

Aeglea BioTherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 16, 2023

Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Program Updates

March 1, 2023

Aeglea BioTherapeutics Announces Update to Corporate Structure to Increase Operational Efficiency

January 5, 2023

Decks in 2023